Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening

Overview

This randomized clinical trial studies home-based HPV or clinic-based Pap screening for cervical cancer. It is not yet known whether home-based screening is more effective, cost-effective, and/or acceptable than clinic-based screening for cervical cancer.

Full Title of Study: “Cytology vs. at Home HPV Screening for Detection of CIN 2,3,CIS”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Screening
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 16, 2017

Detailed Description

PRIMARY OBJECTIVES: I. Compare the sensitivity and specificity for cervical intraepithelial neoplasia (CIN) of two screening approaches: – Novel approach: every 3 years high risk-human papillomavirus (HR-HPV) testing of (at home) self-collected samples with in-clinic cytology of HR-HPV positive women and referral to colposcopy of women with cytology > atypical squamous cells of uncertain significance (ASCUS); repeat HPV testing of HR-HPV positive but cytology negative women at one year; – Currently recommended approach: for women < 30: every 3 years in-clinic cytology screening, with HPV based triage of women with ASCUS and referral to colposcopy of all women with squamous intraepithelial lesion (SIL) and/or HPV+ ASCUS; for women 30+, screening by Papanicolaou (Pap) and HPV, every 2-3 year (depending on previous history) with referral to colposcopy of those who are HPV 16/18+ or with cytology > ASCUS; retesting of those who are positive for other HR-HPV at one year. II. Compare these two approaches with respect to overall cost-effectiveness and acceptability. III. Determine the performance and cost-effectiveness of each approach in vaccinated and unvaccinated women < 30. OUTLINE: Participants are randomized to 1 of 2 arms. GROUP I (home-based HPV screening): Participants collect 2 vaginal specimens using polyester swabs. Participants with a positive HPV test result will have a Pap test. Participants with an abnormal Pap test will undergo standard of care as in Group II. GROUP II (clinic-based standard of care screening): Participants undergo Pap testing. Participants with a positive Pap test undergo standard of care, including colposcopy, HPV testing, cervical biopsy and/or endocervical curettage (ECC). Participants with cervical biopsies showing precancerous changes requiring treatment may undergo loop electrosurgical excision procedure (LEEP) or are referred to appropriate care.

Interventions

  • Other: Cervical Papanicolaou Test
    • Undergo standard of care Pap test screening
  • Other: Cytology Specimen Collection Procedure
    • Undergo home-based HPV screening
  • Other: Questionnaire Administration
    • Ancillary studies
  • Procedure: Screening Method
    • Undergo standard of care Pap test screening
  • Procedure: Screening Method
    • Undergo home-based HPV screening

Arms, Groups and Cohorts

  • Experimental: Group I (home-based HPV screening)
    • Participants collect 2 vaginal specimens using polyester swabs that are then placed in a specimen tube. Specimens are then submitted to the Harborview Medical Center clinical pathology lab. Participants with a positive HPV test result will have a Pap test. Participants with an abnormal Pap test will undergo standard of care as in Group II.
  • Experimental: Group II (clinic-based standard of care screening)
    • Participants undergo standard of care cervical cancer screening and follow-up. That is, participants undergo Pap testing. Participants with an abnormal Pap test undergo HPV testing, colposcopy, cervical biopsy and/or ECC. Participants with cervical biopsies showing precancerous changes are offered to undergo LEEP or are referred to appropriate care.

Clinical Trial Outcome Measures

Primary Measures

  • Cost-effectiveness in the novel approach in vaccinated and unvaccinated women less than 30 years old
    • Time Frame: Up to 4 years
  • Cost-effectiveness in the standard approach in vaccinated and unvaccinated women less than 30 years old
    • Time Frame: Up to 4 years
  • Overall cost-effectiveness and acceptability
    • Time Frame: Up to 4 years
    • The results from the trial (sensitivity, specificity, and costs) will be used in conjunction with a Markov model to determine cost per LY and cost per QALY. Model outcomes (per 100,000 screened) will include the expected numbers of false-positive test results, colposcopies, cases of CIN 1+, cases of cancer, cancer deaths, life expectancy and quality adjusted life-expectancy. Strategies will be compared using incremental cost-effectiveness ratios. Costs and outcomes will be discounted at 3% annually. One, 2-way and probabilistic sensitivity analyses conducted for all inputs to the models.
  • Sensitivity and specificity for CIN 1+ of currently recommended in-clinic cytology screening
    • Time Frame: Up to 4 years
    • An intention-to-treat analysis, based upon the initial randomization, will be performed to evaluate differences between study arms (screening strategies). Estimates of sensitivity and specificity for detection of CIN 1+ will be calculated for the two screening strategies using standard methodologies.
  • Sensitivity and specificity for CIN 1+ of novel home-based testing
    • Time Frame: Up to 4 years
    • An intention-to-treat analysis, based upon the initial randomization, will be performed to evaluate differences between study arms (screening strategies). Estimates of sensitivity and specificity for detection of CIN 1+ will be calculated for the two screening strategies using standard methodologies.
  • Sensitivity and specificity of the novel approach in vaccinated women less than 30 years old
    • Time Frame: Up to 4 years
    • Estimates of sensitivity and specificity for detection of CIN 1+ will be calculated for the two screening strategies and the rate of disease in the 10% sample of test negative subjects in each arm will be extrapolated to the entire study group of test negative subjects in that arm when sensitivity and specificity estimates are calculated. Threshold analyses will also be conducted to identify the range for the cost of the home-based test due to inherent uncertainty
  • Sensitivity and specificity of the standard approach in vaccinated women less than 30 years old
    • Time Frame: Up to 4 years
    • Estimates of sensitivity and specificity for detection of CIN 1 will be calculated for the two screening strategies and the rate of disease in the 10% sample of test negative subjects in each arm will be extrapolated to the entire study group of test negative subjects in that arm when sensitivity and specificity estimates are calculated. Threshold analyses will also be conducted to identify the range for the cost of the home-based test due to inherent uncertainty

Participating in This Clinical Trial

Inclusion Criteria

  • Able to provide informed consent in English Exclusion Criteria:
  • Have had hysterectomy – Currently pregnant – Received treatment of cervical dysplasia with LEEP, cone biopsy, laser procedure or cryotherapy within THREE years – Received colposcopy of cervix within TWO years – Received Pap test within ONE year – Immunocompromised (positive human immunodeficiency virus [HIV] test, transplant recipient, received chemotherapy for cancer, or taking immunosuppressant drugs) – Decisionally impaired adults requiring a legally authorized representative
  • Gender Eligibility: Female

    Minimum Age: 21 Years

    Maximum Age: N/A

    Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

    Investigator Details

    • Lead Sponsor
      • University of Washington
    • Collaborator
      • National Cancer Institute (NCI)
    • Provider of Information About this Clinical Study
      • Sponsor
    • Overall Official(s)
      • Nancy Kiviat, Principal Investigator, Fred Hutch/University of Washington Cancer Consortium

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.